Use of fructose-based compounds for the diagnosis of cancer
This invention relates to compositions, methods utilizing fructose and other monosaccharides for the diagnosis of cancer. Cancer cells have shown a higher level of fructose utilization as compared to glucose. Further, cancer cells have shown a preferential use of fructose for nucleic acid synthesis. The present invention takes advantage of these features and provides for fructose or fructose-based compositions for the diagnosis of cancer using imaging techniques such as positron emission tomography.
1. A method for diagnosing cancer in a mammal, comprising:
administering a detectable quantity of a radiolabeled fructose or deoxyfructose to the mammal; and
imaging the mammal at least 180 minutes after administering the detectable quantity of the radiolabeled fructose or deoxyfructose to the mammal to detect a signal from the radiolabel from the fructose or deoxyfructose,
wherein a presence of a higher accumulation of the signal in comparison to noncancerous tissue of the same type indicates a presence of cancer in the mammal, and the absence of a higher accumulation of the signal in comparison to noncancerous tissue of the same type indicates the absence of cancer in the mammal.
2. The method of claim 1 , wherein the mammal has intolerance to glucose.
3. The method of claim 1 , wherein the radiolabeled fructose or deoxyfructose is metabolized and/or utilized for nucleic acid synthesis.
4. The method of claim 1 , wherein the radiolabel of the radiolabeled fructose or the radiolabeled deoxyfructose is a radioactive isotope of fluorine, iodine, gallium, technetium, indium or copper.
5. The method of claim 1 , wherein the radiolabel of the radiolabeled fructose or the radiolabeled deoxyfructose is a radioactive isotope of fluorine.
6. The method of claim 1 , wherein the radiolabel of the radiolabeled fructose or the radiolabeled deoxyfructose is on the first and/or the second carbon atom of the radiolabeled fructose or the radiolabeled deoxyfructose.
7. The method of claim 1 , wherein the deoxyfructose is deoxyfluorofructose.
8. The method of claim 7 , wherein the deoxyfluorofructose is 1-deoxy-1-fluoro-fructose.
9. The method of claim 7 , wherein the deoxyfluorofructose is 1-deoxy-2-fluoro-fructose.
10. The method of claim 1 , wherein imaging the mammal comprises imaging the mammal after at least 4 hours, at least 24 hours, at least 36 hours, or at least 48 hours after administering the detectable quantity of radiolabeled fructose or the radiolabeled deoxyfructose.
11. The method of claim 1 , wherein imaging the mammal comprises imaging the mammal after the radiolabeled fructose or deoxyfructose is utilized by the cell for nucleic acid synthesis.
12. The method of claim 1 , wherein imaging the mammal comprises using a technique selected from the group consisting of positron emission tomography (PET), computed tomography, magnetic resonance imaging, and combinations thereof.
13. A method for diagnosing cancer in a mammal, comprising:
administering a detectable quantity of a radioactive fructose or deoxyfructose to the mammal; and
imaging the mammal at least 180 minutes after administering the detectable quantity of the radioactive fructose or deoxyfructose to the mammal to detect a radioactive signal from the fructose or deoxyfructose,
wherein a presence of a higher accumulation of the signal in comparison to noncancerous tissue of the same type indicates the presence of cancer in the mammal, and the absence of a higher accumulation of the signal in comparison to noncancerous tissue of the same type indicates the absence of cancer in the mammal.
14. The method of claim 13 , wherein the radioactive fructose or deoxyfructose is metabolized and/or utilized for nucleic acid synthesis.
15. The method of claim 13 , wherein the radioactive fructose or deoxyfructose comprises a radioactive carbon isotope at the first and/or the second carbon atom.
16. The method of claim 13 , wherein imaging the mammal comprises imaging the mammal after the radioactive fructose or deoxyfructose is utilized for nucleic acid synthesis.
17. The method of claim 13 , wherein imaging the mammal comprises using a technique selected from the group consisting of positron emission tomography (PET), computed tomography, magnetic resonance imaging and combinations thereof.
18. The method of claim 14 , wherein the radioactive fructose or deoxyfructose comprises a 13 C isotope.
19. A method for diagnosing cancer in a mammal, comprising:
administering a detectable quantity of radiolabeled 1-deoxy-1-fluoro-fructose; and
imaging the mammal at least 180 minutes after administering the detectable quantity of the radiolabeled 1-deoxy-1-fluoro-fructose to the mammal to detect a signal from the radiolabel from the 1-deoxy-1-fluoro-fructose,
wherein a presence of a higher accumulation of the signal in comparison to noncancerous tissue of the same type indicates a presence of cancer in the mammal, and the absence of a higher accumulation of the signal from the radiolabel or radioactive signal in comparison to noncancerous tissue of the same type indicates the absence of cancer in the mammal.
20. The method of claim 19 , wherein imaging the mammal comprises imaging the mammal after at least 4 hours, at least 24 hours, at least 36 hours, or at least 48 hours after administering the detectable quantity of 1-deoxy-1-fluoro-fructose.
21. The method of claim 19 , wherein imaging the mammal comprises imaging the mammal after the 1-deoxy-1-fluoro-fructose is utilized by the cell for nucleic acid synthesis.
22. The method of claim 19 , wherein imaging the mammal comprises using a technique selected from the group consisting of positron emission tomography (PET), computed tomography, magnetic resonance imaging, and combinations thereof
23. The method of claim 19 , wherein the 1-deoxy-1-fluoro-fructose is 1-deoxy-1-[ 18 F] fluoro-D-fructose.